OverviewSuggest Edit

BioNTech is a biopharmaceutical company developing therapies against cancer and infectious diseases. It provides peptide manufacturing services, GMP (good manufacturing practice) manufacturing services for mRNA and cell and gene therapies, and research services. The company also develops and manufactures biomarker-based in vitro diagnostic devices (IVDD) and commercializes products through selected partners. BioNTech covers a range of platforms, including mRNA therapeutics, engineered cell therapies, antibodies, and small molecule immunomodulators.
TypePublic
Founded2008
HQMainz, DE
Websitebiontech.de
Employee Ratings3.5

Latest Updates

Employees (est.) (Dec 2019)1,300(+19%)
Job Openings221
Revenue (FY, 2019)€2 M(-98%)
Share Price (Jun 2021)€189.9(+6%)
Cybersecurity ratingBMore

Key People/Management at BioNTech

Sean Marett

Sean Marett

Chief Business and Chief Commercial Officer
Ugur Sahin

Ugur Sahin

Chief Executive Officer
Sierk Poetting

Sierk Poetting

Chief Financial Officer and Chief Operating Officer
Ryan Richardson

Ryan Richardson

Chief Strategy Officer
Ozlem Tureci

Ozlem Tureci

Chief Medical Officer
Richard Gaynor

Richard Gaynor

President of BioNTech US and Chief of R&D
Show more

BioNTech Office Locations

BioNTech has offices in Mainz, Halle (Saale), Idar-Oberstein, Marburg and in 4 other locations
Mainz, DE (HQ)
An der Goldgrube 12
Halle (Saale), DE
Weinbergweg 23
Idar-Oberstein, DE
Vollmersbachstraße 66
Marburg, DE
Emil-von-Behring-Straße 76
Neuried, DE
Forstenrieder Str. 8
Planegg, DE
Am Klopferspitz 19a
Show all (8)

BioNTech Financials and Metrics

BioNTech Revenue

BioNTech's revenue was reported to be €1.99 m in FY, 2019
EUR

Net income (FY, 2020)

15.2m

EBIT (FY, 2020)

(82.4m)

Market capitalization (4-Jun-2021)

45.0b

Closing stock price (4-Jun-2021)

189.9

Cash (31-Dec-2020)

1.2b

EV

44.1b
BioNTech's current market capitalization is €45 b.
EURFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

61.6m127.6m2.0m

Revenue growth, %

107%

Cost of goods sold

9.3m13.7m17.4m59.3m

Gross profit

52.3m113.9m(15.4m)
Annual
EURFY, 2017FY, 2018FY, 2019FY, 2020

Cash

172.1m411.5m519.1m1.2b

Accounts Receivable

4.6m18.9m11.9m165.5m

Inventories

11.7m64.1m

Current Assets

172.1m449.0m560.2m1.7b
Quarterly
EURQ2, 2019

Cash

284.9m

Accounts Receivable

8.9m

Current Assets

504.3m

PP&E

123.1m
Annual
EURFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(85.9m)(48.3m)(179.2m)15.2m

Depreciation and Amortization

10.5m22.0m33.9m38.7m

Inventories

(574.0k)(1.3m)

Cash From Operating Activities

(4.6m)(58.2m)(198.5m)(13.5m)
Quarterly
EURQ2, 2018Q2, 2019

Net Income

(23.3m)(90.8m)

Depreciation and Amortization

8.8m15.6m

Inventories

(902.0k)(1.4m)

Cash From Operating Activities

(69.7m)(85.7m)
EURFY, 2017

Debt/Equity

-1.1 x

Debt/Assets

0.1 x

Financial Leverage

-7.8 x
Show all financial metrics

BioNTech Operating Metrics

Oct, 2019

Patents (US)

45

Phase I Trials Products

8

Phase II Trials Products

1

Pre-Clinical Phase Products

11
Show all operating metrics

BioNTech Acquisitions / Subsidiaries

Company NameDateDeal Size
Apta IT
BioNTech Austria Beteiligungen GmbH
BioNTech Business Services
BioNTech Cell & Gene Therapies
BioNTech Diagnostics
BioNTech Innovative Manufacturing Services
BioNTech Protein Therapeutics
BioNTech Real Estate GmbH & Co. KG
BioNTech Real Estate Verwaltungs
BioNTech Research and Development
Show more

BioNTech Revenue Breakdown

Embed Graph

BioNTech revenue breakdown by business segment: 20.2% from Other Sales Transactions and 79.8% from Collaboration Revenue

BioNTech Cybersecurity Score

Cybersecurity ratingPremium dataset

B

89/100

SecurityScorecard logo

BioNTech Online and Social Media Presence

Embed Graph

BioNTech News and Updates

Worldwide mRNA Vaccines and Therapeutics Industry to 2031 - Featuring Arcturus Therapeutics Holdings, BioNTech and CureVac Among Others

DUBLIN, June 1, 2021 /PRNewswire/ -- The "Global mRNA Vaccines and Therapeutics Market: Focus on Application, mRNA Type, Country Data (13 Countries), and Competitive Landscape - Analysis and Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering. The publisher's...

Pfizer and BioNTech Receive First Authorization in European Union for COVID-19 Vaccine in Adolescents

NEW YORK and MAINZ, GERMANY, May 28, 2021 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the Conditional Marketing Authorization (CMA) for COMIRNATY® in the European Union (EU) has been expanded to include individuals 12 to 15 years of age. This follows the European Me…

BioNTech says COVID-19 vaccine likely to be effective against Indian coronavirus variant

BioNTech's chief executive has said that the COVID-19 vaccine it developed with U.S. pharmaceutical group Pfizer is likely to be effective against the Indian variant of coronavirus. The German biotechnology company's CEO, Ugur Sahin, said on Thursday in a meeting with the Turkish health minister t…

BioNTech Publishes First Sustainability Report and Receives “Prime” Rating by ISS ESG

MAINZ, Germany, May 21, 2021 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), a next generation immunotherapy company pioneering novel therapies for cancer and infectious diseases, has published its first Sustainability Report. The report focuses on the Company’s commitment to making an im…

UPDATE: Pfizer and BioNTech to supply EU with up to 1.8 billion additional COVID vaccine doses

Pfizer Inc. and German partner BioNTech SE said Thursday they have reached a new agreement with the European Commission to supply up to 1.8 billion additional doses of their COVID-19 vaccine. The partners said the agreement is to provide 900 million doses initially with an option for the EC to req…

Pfizer and BioNTech to Supply the European Union with up to 1.8 Billion Additional Doses of COMIRNATY®

NEW YORK AND MAINZ, GERMANY, May 20, 2021 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a new agreement with the European Commission (EC) to supply 900 million doses of COMIRNATY®, the companies’ COVID-19 vaccine, to the European Union (EU), with an option for the EC to re…
Show more

BioNTech Blogs

home-rebrush

home-rebrush admin Tue, 03/30/2021 - 07:37

Overview COVID-19

Overview COVID-19 admin Wed, 12/02/2020 - 00:45

HCP 5 Biontechs Sars-Cov-2 Vaccine Candidates

HCP 5 Biontechs Sars-Cov-2 Vaccine Candidates admin Sun, 11/29/2020 - 20:09

HCP 1 The Virus Sars Cov 2

HCP 1 The Virus Sars Cov 2 admin Sun, 11/29/2020 - 20:09

HCP 2 The Disease COVID-19

HCP 2 The Disease COVID-19 admin Sun, 11/29/2020 - 20:09

HCP 3 Role of Vaccines in Pandemic

HCP 3 Role of Vaccines in Pandemic admin Sun, 11/29/2020 - 20:09
Show more

BioNTech Frequently Asked Questions

  • When was BioNTech founded?

    BioNTech was founded in 2008.

  • Who are BioNTech key executives?

    BioNTech's key executives are Sean Marett, Ugur Sahin and Sierk Poetting.

  • How many employees does BioNTech have?

    BioNTech has 1,300 employees.

  • Who are BioNTech competitors?

    Competitors of BioNTech include Ohm Oncology, Kite Pharma and 3sbio.

  • Where is BioNTech headquarters?

    BioNTech headquarters is located at An der Goldgrube 12, Mainz.

  • Where are BioNTech offices?

    BioNTech has offices in Mainz, Halle (Saale), Idar-Oberstein, Marburg and in 4 other locations.

  • How many offices does BioNTech have?

    BioNTech has 8 offices.